/PVLA

Palvella Therapeutics Inc

PVLA

$150.13USD↓-0.17%-0.26 today

MARKET CAP

2.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$150 – $154

52W RANGE

$53

$161

AI Summary

Stalk

Buy NowMedium

PVLA is in a Stage 2 advancing structure with rising EMAs and a dominant Higher Highs & Higher Lows pattern indicating persistent demand. The medium-term bias is bullish, and the current pullback into the rising 9- and 20-EMA zone offers a favorable speculative entry. Maintaining discipline around this support area aligns with trend momentum, while a decisive break below EMAs would invalidate the bullish posture.

↑Phase III SELVA trial delivered 95% patient response for Cuturin Rapamycin.
↑Addressable market of 30,000 U.S. patients implies multibillion-dollar potential.
↓Negative profitability metrics and high leverage indicate financial strain.

Full analysis →

Buying

6

institutions

Selling

5

institutions

New Positions

2

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	918.36 K	140.34 M	+231.50 K	+63.9%	0.00%
WP Woodline Partners LP Q2 2026	SELL	317.52 K	48.52 M	+-317.52 K	-38.7%	0.15%
RT Renaissance Technologies LLC Q2 2026	BUY	53.27 K	8.14 M	+35.30 K	+263.4%	0.01%
MM Millennium Management LLC Q2 2026	SELL	52.21 K	7.98 M	+-41.43 K	-31.6%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	47.22 K	7.22 M	+-9.25 K	+2.5%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	44.54 K	6.81 M	+-52.19 K	-43.5%	0.01%
JC Jpmorgan Chase & Co Q2 2026	BUY	8.42 K	1.30 M	+2.90 K	+113.5%	0.00%
JH Janus Henderson Group Plc Q1 2026	BUY	7.20 K	899.89 K	+3.60 K	+139.2%	0.00%
AC Aqr Capital Management LLC Q2 2026	BUYNEW	2.32 K	353.93 K	+2.32 K	+0.0%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	2.18 K	333.15 K	+2.18 K	+0.0%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	SELL	0.00	0.00	+-88.16 K	-100.0%	0.00%